BA
RNAC icon

BlackRock Advisors’s Cartesian Therapeutics RNAC Stock Holding History

BlackRock Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$33K Buy
65
+49
+306% +$28.6K ﹤0.01% 3349
2016
Q3 		$7K Buy
+16
New +$6.25K ﹤0.01% 3618

Other funds holding RNAC

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock Advisors's RNAC Position: Q4 2016 in Review

BlackRock Advisors increased its Cartesian Therapeutics (RNAC) stake by 306% in Q4 2016, buying an estimated $28.6K and bringing the position to 65 shares worth $33K. The position accounts for ﹤0.01% of the portfolio, ranked #3349.

BlackRock Advisors first reported a position in RNAC in Q3 2016 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold RNAC as of Q4 2016.

  • BlackRock Advisors held 65 shares of Cartesian Therapeutics worth $33K as of Q4 2016.
  • BlackRock Advisors bought 49 Cartesian Therapeutics shares in Q4 2016, an estimated $28.6K.
  • Cartesian Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3349 holding.
  • BlackRock Advisors first reported a position in Cartesian Therapeutics in Q3 2016 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.